Shares of Syros Pharmaceuticals Inc (NASDAQ:SYRS) have received a consensus recommendation of “Buy” from the ten research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $23.83.
Several equities analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday. HC Wainwright reissued a “hold” rating and set a $10.00 price target on shares of Syros Pharmaceuticals in a report on Thursday, December 21st. JMP Securities raised shares of Syros Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $33.00 price target for the company in a report on Thursday, September 28th. Piper Jaffray Companies reissued an “overweight” rating and set a $30.00 price target on shares of Syros Pharmaceuticals in a report on Tuesday, October 31st. Finally, Oppenheimer set a $28.00 price target on shares of Syros Pharmaceuticals and gave the company a “buy” rating in a report on Monday.
Shares of Syros Pharmaceuticals (SYRS) traded up $0.34 during trading on Monday, hitting $10.73. 299,600 shares of the stock traded hands, compared to its average volume of 249,671. Syros Pharmaceuticals has a 1-year low of $6.30 and a 1-year high of $24.38. The firm has a market cap of $280.85 and a price-to-earnings ratio of -6.17.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Wednesday, November 8th. The company reported ($0.53) earnings per share for the quarter, meeting the consensus estimate of ($0.53). equities research analysts anticipate that Syros Pharmaceuticals will post -2.12 EPS for the current year.
In related news, Director Srinivas Akkaraju bought 109,774 shares of the company’s stock in a transaction on Thursday, December 14th. The stock was bought at an average cost of $9.03 per share, with a total value of $991,259.22. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jeremy P. Springhorn bought 15,000 shares of the company’s stock in a transaction on Friday, December 15th. The stock was bought at an average cost of $9.08 per share, with a total value of $136,200.00. The disclosure for this purchase can be found here. Insiders own 33.60% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in SYRS. Nationwide Fund Advisors raised its stake in shares of Syros Pharmaceuticals by 249.8% during the second quarter. Nationwide Fund Advisors now owns 7,024 shares of the company’s stock worth $113,000 after buying an additional 5,016 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Syros Pharmaceuticals during the third quarter worth approximately $133,000. Cubist Systematic Strategies LLC bought a new stake in shares of Syros Pharmaceuticals during the third quarter worth approximately $149,000. The Manufacturers Life Insurance Company raised its stake in shares of Syros Pharmaceuticals by 11,253.8% during the second quarter. The Manufacturers Life Insurance Company now owns 10,559 shares of the company’s stock worth $170,000 after buying an additional 10,466 shares during the last quarter. Finally, Rhumbline Advisers bought a new stake in shares of Syros Pharmaceuticals during the second quarter worth approximately $198,000. 57.96% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://ledgergazette.com/2018/01/11/brokerages-set-syros-pharmaceuticals-inc-syrs-pt-at-22-23.html.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.